Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) Equity Average (2019 - 2025)

IDEAYA Biosciences' Equity Average history spans 7 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 5.56% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 5.56%, while the annual FY2025 figure was $1.0 billion, 23.92% up from the prior year.
  • Equity Average for Q4 2025 was $1.1 billion at IDEAYA Biosciences, up from $1.0 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.1 billion in Q4 2024 and bottomed at $215.7 million in Q1 2021.
  • The 5-year median for Equity Average is $461.3 million (2023), against an average of $606.3 million.
  • The largest annual shift saw Equity Average surged 127.79% in 2024 before it decreased 5.56% in 2025.
  • A 5-year view of Equity Average shows it stood at $309.6 million in 2021, then increased by 16.0% to $359.1 million in 2022, then surged by 57.21% to $564.6 million in 2023, then skyrocketed by 98.34% to $1.1 billion in 2024, then decreased by 5.56% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Equity Average are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $991.9 million (Q2 2025).